Kit for assessing the risk of colorectal cancer recurrence after oxaliplatin chemotherapy and its use

Abstract

The invention relates to a kit for evaluating the colorectal cancer relapse risk after Oxaliplatin chemotherapy and application thereof. The kit comprises a first primer pair for amplifying the internal reference gene GAPDH, a second primer pair for amplifying the gene PTK2, a third primer pair for amplifying the gene WNK1, a fourth primer pair for amplifying the gene STK39, a fifth primer pair for amplifying the gene DNAJC6, a sixth primer pair for amplifying the gene NME4, a seventh primer pair for amplifying the gene BRD2, an eighth primer pair for amplifying the gene PPP3R1, a ninth primer pair for amplifying the gene EYA4 and a tenth primer pair for amplifying the gene STK32A. The kit can be used for evaluating the relapse risk after a colorectal cancer patient uses chemotherapy medicine for inducing DNA damage.

Description

[Technical Field] [0001] The invention relates to a drug detection kit, in particular to a kit for assessing the risk of colorectal cancer recurrence after oxaliplatin chemotherapy and its use. [Background technique] [0002] Colorectal cancer is one of the most common malignant tumors. The incidence rate in China is on the rise, ranking third among all malignant tumors, posing a serious threat to human health. [0003] With the development of molecular analysis methods, various new diagnosis and treatment methods and new drugs are constantly emerging, and the treatment effect of colorectal cancer has been significantly improved. However, although traditional clinicopathological factors can provide certain efficacy information for patients with colorectal cancer, the extent to which these risk factors affect the prognosis of colorectal cancer cannot be well quantified and integrated. Therefore, for individual patients, the current treatment methods And the choice of medication sti...

AI Technical Summary

Problems solved by technology

However, oxaliplatin, as the first-line drug for adjuvant chemotherapy after radical resection for patients with stage III colorectal cancer recommended by the National Comprehensive Cancer Network guidelines (NCCN), currently has no effective predictive tools for clinicians to use. Personalize drug therapy for CRC patients by distinguishing patient groups who may or may not benefit more from oxaliplatin-adjuvant chemotherapy

This reality severely limits the efficacy of oxaliplatin in postoperative adjuvant chemotherapy for stage III colorectal cancer, and 35% of patients with stage III colorectal cancer cannot benefit from postoperative adjuvant chemotherapy with oxaliplatin (Uncu D , Aksoy S, Cetin B, et al. Results of adjuvant FOLFOX regimenmensin stage III colorectal cancer patients: retrospective analysis of 667 patients. Oncology. 2013; 84(4): 240-245)

Images